|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Johns Hopkins University |
|---|---|
| Information provided by: | Johns Hopkins University |
| ClinicalTrials.gov Identifier: | NCT00127114 |
Purpose
The purpose of this clinical trial is to test whether or not the medication amantadine is effective in reducing behavioral disturbances in patients with frontotemporal dementia.
| Condition | Intervention | Phase |
|---|---|---|
|
Dementia |
Drug: amantadine |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) |
| Estimated Enrollment: | 52 |
| Study Start Date: | September 2005 |
Behavioral disturbances are a major cause of morbidity in frontotemporal dementia (FTD), yet little is known about the effectiveness of medications to treat these disturbances. Preliminary data suggests that the dopaminergic agent amantadine may reduce these disturbances. This 6-week, prospective, randomized, placebo-controlled trial will compare amantadine to placebo to assess its effectiveness in reducing behavioral symptoms.
Eligibility| Ages Eligible for Study: | 40 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Maryland | |
| Johns Hopkins University School of Medicine, Outpatient General Clinical Research Center | |
| Baltimore, Maryland, United States, 21287 | |
| Principal Investigator: | David M Blass, M.D. | Johns Hopkins University |
More Information
| Responsible Party: | Johns Hopkins University School of Medicine ( Dr. David Mark Blass ) |
| Study ID Numbers: | 04033101 |
| Study First Received: | August 3, 2005 |
| Last Updated: | March 16, 2009 |
| ClinicalTrials.gov Identifier: | NCT00127114 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Behavioral disturbance Frontotemporal dementia Dementia Amantadine Behavioral disturbance due to frontotemporal dementia |
|
Pick Disease of the Brain Anti-Infective Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Antiparkinson Agents Brain Diseases Aphasia, Primary Progressive Signs and Symptoms Sensory System Agents Mental Disorders Therapeutic Uses Analgesics Dementia |
Neurobehavioral Manifestations Speech Disorders Aphasia Nervous System Diseases Language Disorders Central Nervous System Diseases Antiviral Agents Pharmacologic Actions Delirium, Dementia, Amnestic, Cognitive Disorders Analgesics, Non-Narcotic Neurologic Manifestations Dopamine Agents Peripheral Nervous System Agents Amantadine Central Nervous System Agents |